Clinical Data Shows Noxopharm’s Veyonda® May Prevent Cytokine Storm
Australian clinical-stage drug development company Noxopharm Limted (ASX:NOX) today announced that in a cohort of 18 patients with moderately severe cases of COVID-19, interim data in its NOXCOVID study suggests Veyonda provides protection against progression of the severe inflammation associated with a worsening of the disease.
“Until enough people are vaccinated to achieve global herd immunity in the face of waves of emerging mutant strains of the virus, millions of people are likely to continue to suffer severe COVID-19 disease involving major disabilities and death,” said Noxopharm CEO Graham Kelly . “That is where we see Veyonda playing a key role, with its STING blocking action stopping the destructive inflammatory process in patients with moderate COVID-19. The interim data released today points to Veyonda delivering on this promise.”
The major challenge for hospital services during the current pandemic is the high level of care required for those patients experiencing rapid deterioration of lung function, leading to acute respiratory distress syndrome, septic shock, and major disabilities or death. A key factor associated with disease worsening is the excessive production of inflammatory factors normally invoked to facilitate tissue repair and combat infection in a process known as the cytokine storm.
Biomarker data from the top Veyonda dose cohort is expected within the next few weeks. That will be followed by a review of the final clinical data on completion of treatment of the final patient. Clinical status (WHO COVID-19 grade, comorbidities) and other therapies will be considered, and after reviewing all the data, the Company will then consult with government, regulatory, medical, and business development advisors.
Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and septic shock. Veyonda® is the Company’s first pipe-line drug candidate currently in Phase 2 clinical trialing. Veyonda has two main drug actions – a moderating effect on the ceramide/sphingosine-1-phosphate balance and inhibition of STING signaling. Activity against the former target contributes to its dual-acting oncotoxic and immuno-oncology functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiotherapy and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, also contributing to an anti-cancer action, but also potentially blocking septic shock.
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KYOWA-KIRIN23.7.2021 16:07:06 CEST | Press release
Kyowa Kirin Provides Update on Application for Marketing Authorisation of Istradefylline in Europe for the Treatment of ‘OFF’ Episodes in People Living with Parkinson’s
FORUMPAY23.7.2021 15:18:10 CEST | Press release
ForumPay Teams Up with Bambora to Conquer the Crypto-to-Fiat Payments Market
NY-WIPRO-LIMITED23.7.2021 14:56:09 CEST | Press release
Wipro Recognized as 2021 Microsoft Modernizing Applications Partner of the Year
MERCK23.7.2021 13:47:13 CEST | Press release
Merck Announces Appointment of Head of China & International for Healthcare
FL-H.I.G.-WHITEHORSE23.7.2021 13:05:10 CEST | Press release
H.I.G. WhiteHorse Refinances Grupo Recoletas
SCHLUMBERGER-LIMITED23.7.2021 12:52:09 CEST | Press release
Schlumberger Announces Second-Quarter 2021 Results
WYSS-CENTER23.7.2021 12:01:06 CEST | Press release
Wyss Center Partners With Artiria Medical to Accelerate a Novel Therapy for Cerebral Vasospasm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom